Scinai Immunotherapeutics
SCNI
3 hedge funds and large institutions have $122K invested in Scinai Immunotherapeutics in 2016 Q1 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, reducing their positions, and 0 closing their positions.
50% more funds holding
Funds holding: 2 → 3 (+1)
3% less capital invested
Capital invested by funds: $126K → $122K (-$4K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRCT
Tower Research Capital (TRC)
New York
|
+$2.95K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
VIA
1
Vantage Investment Advisors
State College,
Pennsylvania
| $63K | – | – | – |
|
2
Bank of Montreal
Toronto,
Ontario, Canada
| $56K | – | – | – |
|
|
TRCT
3
Tower Research Capital (TRC)
New York
| $3K | +$2.95K | +8 | New |
|
SCNI Hedge Fund Activity: Q1 2016 in Review
3 of the 3,754 institutional investors tracked by Wall St. Rank reported a position in Scinai Immunotherapeutics (SCNI) for Q1 2016, worth a combined $122K — down 3.2% from $126K a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new SCNI positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Tower Research Capital (TRC), opening a new position worth an estimated $2.95K.
- 3 institutional investors held Scinai Immunotherapeutics (SCNI) as of Q1 2016, up from 2 in Q4 2015.
- Funds reported $122K of Scinai Immunotherapeutics stock for Q1 2016, down 3.2% quarter-over-quarter.
- 1 fund opened new Scinai Immunotherapeutics positions in Q1 2016 and 0 closed out, a net change of +1 holder.
- The largest Scinai Immunotherapeutics buyer in Q1 2016 was Tower Research Capital (TRC), an estimated $2.95K added.
Based on aggregated 13F filings for Q1 2016.